Merck (MRK) Non-Current Debt (2009 - 2026)
Merck (MRK) posted quarterly Non-Current Debt of $46.7 billion for Q1 2026, up 39.39% year-over-year from $33.5 billion in Q1 2025, and little changed quarter-over-quarter from $46.8 billion in Q4 2025.
Merck (MRK) Non-Current Debt (2009 - 2026) Analysis & Trends
Merck (MRK) has reported Non-Current Debt for 18 consecutive years, with $46.7 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Debt rose 39.39% year-over-year to $46.7 billion; the TTM figure through Mar 2026 stood at $46.7 billion (up 39.39% YoY), while the FY2025 annual figure was $46.8 billion, up 35.66% from the prior year.
- Non-Current Debt steadied at $46.7 billion in Q1 2026 per MRK's latest filing, from $46.8 billion in the prior quarter.
- Across five years, Non-Current Debt topped out at $46.8 billion in Q4 2025 and bottomed at $28.1 billion in Q1 2023.
- Historically, Non-Current Debt has averaged $34.3 billion across 5 years, with a median of $34.0 billion in 2025.
- Annual changes were most pronounced in 2023 — Non-Current Debt fell 8.21% — and 2026, when it jumped 39.39%.
- Merck's Non-Current Debt stood at $28.7 billion in 2022, then climbed by 17.18% to $33.7 billion in 2023, then increased by 2.31% to $34.5 billion in 2024, then surged by 35.66% to $46.8 billion in 2025, then declined by 0.16% to $46.7 billion in 2026.
- Business Quant data shows MRK's Non-Current Debt at $46.7 billion in Q1 2026, $46.8 billion in Q4 2025, and $40.0 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 37.34 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 62.48 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 51.08 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 23.68 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 57.30 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 26.25 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 60.50 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -18.71 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 17.02 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 51.08 Bn |
| Mar 31, 2026 | 46.67 Bn |
| Dec 31, 2025 | 46.75 Bn |
| Sep 30, 2025 | 39.97 Bn |
| Jun 30, 2025 | 33.97 Bn |
| Mar 31, 2025 | 33.48 Bn |
| Dec 31, 2024 | 34.46 Bn |
| Sep 30, 2024 | 34.98 Bn |
| Jun 30, 2024 | 34.72 Bn |
| Mar 31, 2024 | 31.14 Bn |
| Dec 31, 2023 | 33.68 Bn |
| Sep 30, 2023 | 33.97 Bn |
| Jun 30, 2023 | 34.07 Bn |
| Mar 31, 2023 | 28.07 Bn |
| Dec 31, 2022 | 28.75 Bn |
| Sep 30, 2022 | 28.48 Bn |
| Jun 30, 2022 | 28.68 Bn |
| Mar 31, 2022 | 30.59 Bn |
| Dec 31, 2021 | 30.69 Bn |
| Sep 30, 2021 | 22.91 Bn |